Novavax, Inc.
General ticker "NVAX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Novavax, Inc. follows the US Stock Market performance with the rate: 32.6%.
Estimated limits based on current volatility of 1.8%: low 6.69$, high 6.93$
Factors to consider:
- Total employees count: 952 (-38.3%) as of 2024
- North America accounted for 9.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: History of losses, Funding requirements, Labor/talent shortage/retention, Dependence on successful vaccine development, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.34$, 14.93$]
- 2025-12-31 to 2026-12-31 estimated range: [3.84$, 11.32$]
Financial Metrics affecting the NVAX estimates:
- Negative: with PPE of -6.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.80 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.56 <= 3.41
Short-term NVAX quotes
Long-term NVAX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,598.95MM | $556.38MM | $682.16MM |
| Operating Expenses | $2,243.69MM | $1,122.89MM | $931.09MM |
| Operating Income | $-644.74MM | $-566.51MM | $-248.93MM |
| Non-Operating Income | $-8.91MM | $23.48MM | $72.32MM |
| Interest Expense | $19.88MM | $14.42MM | $20.07MM |
| R&D Expense | $1,235.28MM | $737.50MM | $391.17MM |
| Income(Loss) | $-653.65MM | $-543.03MM | $-176.62MM |
| Taxes | $4.29MM | $2.03MM | $10.88MM |
| Profit(Loss)* | $-657.94MM | $-545.06MM | $-187.50MM |
| Stockholders Equity | $-634.08MM | $-716.93MM | $-623.84MM |
| Inventory | $36.68MM | $41.70MM | $8.75MM |
| Assets | $2,258.68MM | $1,797.49MM | $1,560.42MM |
| Operating Cash Flow | $-415.94MM | $-713.97MM | $-87.26MM |
| Capital expenditure | $92.98MM | $58.81MM | $13.06MM |
| Investing Cash Flow | $-92.98MM | $-58.81MM | $-204.04MM |
| Financing Cash Flow | $324.99MM | $4.47MM | $260.58MM |
| Earnings Per Share** | $-8.42 | $-5.41 | $-1.23 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.